

input and feedback, and facilitates collaboration between the Institute and these external partners to advance NCI's authorized programs. It is beneficial for NCI, through the OAR, to pretest strategies, concepts, activities and materials while they are under development. This pre-testing, or formative evaluation, helps ensure that the products and services developed by NCI have the greatest capacity of being received, understood, and accepted by their target audiences.

Additionally, since OAR is responsible for matching advocates to NCI programs and initiatives across the cancer continuum, it is necessary to measure the satisfaction of both internal and external stakeholders with this

collaboration. This customer satisfaction research helps ensure the relevance, utility, and appropriateness of the many initiatives and products that OAR and NCI produce. The OAR will use a variety of qualitative (focus groups, interviews) and quantitative (paper, phone, in-person, and Web surveys) methodologies to conduct this research, allowing NCI to: (1) Understand characteristics (attitudes, beliefs, and behaviors) of the intended target audience and use this information in the development of effective strategies, concepts and activities; (2) use a feedback loop to help refine, revise, and enhance OAR's efforts—ensuring that they have the greatest relevance, utility,

appropriateness, and impact for/to target audiences; and (3) expend limited program resource dollars wisely and effectively. *Frequency of Response:* On occasion. *Affected Public:* Individuals or households; Businesses or other for profit; Not-for-profit institutions and organizations; Federal Government; State, Local, or Tribal Government. *Type of Respondents:* Adult cancer research advocates; members of the public; health care professionals; organizational representatives. The table below outlines the estimated burden hours required for a three-year approval of this generic submission. There are no Capital Costs, Operating Costs, and/or Maintenance Costs to report.

A.12-1—ESTIMATE OF ANNUAL BURDEN HOURS

Survey/instrument	Number of respondents	Frequency of response	Average hours per response	Annual burden hours
Self-Administered Post-Activity Questionnaires .....	1,200	1	20/60 (.33)	400
Other Self-Administered Questionnaires .....	600	1	20/60 (.33)	200
Individual In-Depth Interviews .....	75	1	1.0	75
Focus Group Interviews .....	100	1	1.5	150
<b>Totals .....</b>	<b>1,975</b>	<b>.....</b>	<b>.....</b>	<b>825</b>

*Request for Comments:* Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

**FOR FURTHER INFORMATION CONTACT:** To request more information on the proposed project or to obtain a copy of the data collection plans, contact Elizabeth Neilson, Advocacy Relations Manager, Office of Advocacy Relations (OAR), NCI, NIH, 31 Center Drive, Bldg. 31, Room 10A28, MSC 2580, Bethesda, MD 20892, call non-toll-free number 301-451-3321 or e-mail your request, including your address to: [neilson@mail.nih.gov](mailto:neilson@mail.nih.gov).

*Comments Due Date:* Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

Dated: April 29, 2010.  
**Vivian Horovitch-Kelley,**  
*NCI Project Clearance Liaison, National Institutes of Health.*  
 [FR Doc. 2010-10897 Filed 5-6-10; 8:45 am]  
**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Office of Refugee Resettlement**

**Administration for Children and Families; Single-Source Program Expansion Supplement Grant**

**AGENCY:** Office of Refugee Resettlement, ACF, HHS.

**ACTION:** Notice to award a single-source program expansion supplement grant.

*CFDA Number:* 93.576.  
*Legislative Authority:* This program is authorized by section 412 (c)(1)(A) of the Immigration and Nationality Act (INA) [8 U.S.C. 1522 (c)(1)(A)], as amended, which authorizes the Director "to make grants to, and enter into contracts with, public or private nonprofit agencies for projects specifically designed—(i) To assist

refugees in obtaining the skills which are necessary for economic self-sufficiency, including projects for job training, employment services, day care, professional refresher training, and other recertification services; (ii) to provide training in English where necessary (regardless of whether the refugees are employed or receiving cash or other assistance); and (iii) to provide where specific needs have been shown and recognized by the Director, health (including mental health) services, social services, educational and other services."

*Amount of Award:* \$150,000.  
*Project Period:* December 1, 2009–September 29, 2010.

**SUMMARY:** The Office of Refugee Resettlement (ORR) announces the award of a \$150,000 single-source program expansion supplement to expand the provision of technical assistance to the Ethiopian Community Development Council, Inc. (ECDC), located in Arlington, VA.

Current economic conditions have confronted community-based organizations (CBO) with a dire need for assistance yet limited resources to respond effectively. This supplemental award will support greater outreach and enhanced collaboration to meet these challenges.

Provision of technical assistance is essential to support the long-term

sustainability of programs and services that help newly-arrived refugees secure employment, overcome language and cultural barriers, become economically self-sufficient, and integrate into their new communities.

Through this provision of technical assistance, ECDC will ensure a more effective service component by focusing on reducing social service gaps, increasing refugee access to mainstream resources and services, and helping CBOs build capacity and sustainability.

*Contact for Further Information:*  
Kenneth Tota, Deputy Director, Office of Refugee Resettlement, 901 D Street, SW., Washington, DC 20047. Telephone: 202-401-4858; e-mail: [ktota@acf.hhs.gov](mailto:ktota@acf.hhs.gov).

Dated: April 28, 2010.

**Eskinder Negash,**

*Director, Office of Refugee Resettlement.*

[FR Doc. 2010-10809 Filed 5-6-10; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### Office of Refugee Resettlement; Urgent Single Source Grant to Survivors of Torture International (SOTI)

**AGENCY:** Office of Refugee Resettlement, ACF, HHS.

**ACTION:** Notice to Award an Urgent Single Source Grant to Survivors of Torture International (SOTI).

*CFDA Number:* 93.604.

*Legislative Authority:* "Torture Victims Relief Act (TVRA) of 1998," Public Law 105-320 (22 U.S.C. 2152 note), reauthorized by Public Law 109-165 in January 2006. Section 5(a) provides for "Assistance for Treatment of Torture Victims.—The Secretary of Health and Human Services may provide grants to programs in the United States to cover the cost of the following services: (1) Services for the rehabilitation of victims of torture, including treatment of the physical and psychological effects of torture. (2) Social and legal services for victims of torture. (3) Research and training for health care providers outside of treatment centers, or programs for the purpose of enabling such providers to provide the services described in paragraph (1)."

*Amount of Award:* \$271,000.

*Project Period:* March 1, 2010 through February 28, 2011.

*Summary:* Notice is hereby given that an urgent single-source award will be

made to Survivors of Torture International (SOTI), San Diego, CA, to provide comprehensive rehabilitative services to incoming Iraqi and other survivors of torture, who are in need of specialized services, to regain their health and independence and rebuild productive lives. In addition to providing direct services, SOTI will train area providers to effectively serve this population and leverage resources within the community. SOTI will also focus on building and sustaining collaboration among other providers to serve this population.

In Fiscal Year (FY) 2010, due to an increase in the funding appropriation under the TVRA, an additional amount of \$271,000 is available for direct services through the Office of Refugee Resettlement (ORR) Services for Survivors of Torture Program. In FY 2009, a total of 3,667 Iraqi refugees and holders of Special Immigrant Visas were resettled in the San Diego metropolitan area. Some of these individuals have suffered torture prior to arrival in the United States and are in need of specialized services. San Diego, CA, is the area of the country most heavily impacted in terms of Iraqi refugee arrivals. SOTI has a long history of serving torture survivors in San Diego county, has developed a large network of pro bono providers, is well known in the community, and possesses the clinical and programmatic expertise to serve the survivors.

**FOR FURTHER INFORMATION CONTACT:**

Ronald Munia, Director, Division of Community Resettlement, Office of Refugee Resettlement, 901 D Street, SW., Washington, DC 20047. Telephone: 202-401-4559. E-mail: [Ronald.Munia@acf.hhs.gov](mailto:Ronald.Munia@acf.hhs.gov).

Dated: April 28, 2010.

**Eskinder Negash,**

*Director, Office of Refugee Resettlement.*

[FR Doc. 2010-10810 Filed 5-6-10; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2010-D-0189]

#### Guidance for Industry and Food and Drug Administration Staff; Enforcement Policy Concerning Certain Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco; Availability

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of the guidance entitled "Enforcement Policy Concerning Certain Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco." This guidance document discusses FDA's intended enforcement policies with respect to two provisions of the final regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents. One provision restricts the use of a trade or brand name of a nontobacco product as the trade or brand name for a cigarette or smokeless tobacco product. The second provision requires that labeling or print advertisements appear in a black-and-white text only format, except in certain "adult only" locations or in publications that do not have significant readership by children and adolescents under the age of 18. This guidance document will be implemented immediately, but it remains subject to comment in accordance with the agency's good guidance practices (GGPs).

**DATES:** Submit electronic or written comments on this guidance at any time. General comments on agency guidance documents are welcome at any time.

**ADDRESSES:** Submit written requests for single copies of the guidance document entitled "Enforcement Policy Concerning Certain Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco" to the Center for Tobacco Products, Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850-3229. Send one self-addressed adhesive label to assist that office in processing your request or include a fax number to which the guidance document may be sent. See the **SUPPLEMENTARY INFORMATION** section for information on electronic access to the guidance.

Submit electronic comments to <http://www.regulations.gov>. Submit written comments concerning this guidance to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Identify comments with the docket number found in brackets in the heading of this document.

**FOR FURTHER INFORMATION CONTACT:** Annette Marthaler, Center for Tobacco Products, Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 1-877-287-1373, [annette.marthaler@fda.hhs.gov](mailto:annette.marthaler@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:**